Bay Colony Advisory Group Inc d b a Bay Colony Advisors Has $424,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors lowered its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 45.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,052 shares of the pharmaceutical company’s stock after selling 874 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Vertex Pharmaceuticals were worth $424,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Dunhill Financial LLC grew its stake in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the period. Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth approximately $30,000. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $33,000. Truvestments Capital LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $35,000. Finally, Sugar Maple Asset Management LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on VRTX shares. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Bank of America reduced their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research note on Thursday, December 19th. Royal Bank of Canada raised their price objective on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the company a “sector perform” rating in a research note on Thursday, February 20th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Finally, Piper Sandler reduced their price objective on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $488.29 on Friday. The business’s fifty day simple moving average is $448.27 and its 200 day simple moving average is $461.50. The firm has a market capitalization of $125.39 billion, a P/E ratio of -221.95, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total value of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 1,084 shares of company stock worth $505,512 over the last ninety days. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.